SAN DIEGO, Aug. 14, 2014 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced today that it will host an "Analyst and Investor Day" in San Diego, CA on Tuesday, September 23, 2014. The event will be held at the Company's offices at 9980 Huennekens St. from 10:00am to 4:00pm Pacific Time.
Presentations by TearLab's senior management team will cover the Company's current business and growth strategies, international market opportunities and recent R&D activities, including the development of a second-generation tear testing platform that combines a panel of tests, including Osmolarity, IgE and potentially other biomarkers and tiers, all on a single chip. Following the formal presentations, guests will be invited to participate in a Q&A session.
To attend the live event:
Those wishing to attend the live event should email skilmer@tearlab.com, and include name, title, company and complete contact information.
To access the webcast:
The event will be webcast live and archived for at least 90 days on the Company's website at http://www.tearlab.com under the "Webcasts" tab in the Investors section.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab® Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Forward-Looking Statements
This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press release include statements regarding the future potential of the TearLab Osmolarity System and the related impact on our sales. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the SEC on March 17, 2014, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, filed with the SEC on August 8, 2014. We do not undertake to update any forward-looking statements.